To date, most of the patients who were treated with new therapies, such as MEK inhibitors, presented severe manifestations of RASopathies for which no conventional therapy is available (e.g. severe hypertrophic cardiomyopathy and lymphovascular disease). The gene discussed is MAP2K7; the disease is hypertrophic cardiomyopathy.